Provided by Tiger Trade Technology Pte. Ltd.

Entrada Therapeutics, Inc.

7.33
-0.2400-3.17%
Post-market: 7.330.00000.00%19:30 EDT
Volume:184.25K
Turnover:1.35M
Market Cap:284.56M
PE:-1.85
High:7.58
Open:7.58
Low:7.12
Close:7.57
52wk High:16.45
52wk Low:5.02
Shares:38.82M
Float Shares:26.88M
Volume Ratio:0.96
T/O Rate:0.69%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.9676
EPS(LYR):-3.4746
ROE:-54.09%
ROA:-29.20%
PB:1.22
PE(LYR):-2.11

Loading ...

Entrada Therapeutics Is Maintained at Buy by Guggenheim

Dow Jones
·
Jun 08

Analysts Have Conflicting Sentiments on These Healthcare Companies: Entrada Therapeutics Inc (TRDA) and Pfizer (PFE)

TIPRANKS
·
Jun 08

Oppenheimer Remains a Buy on Entrada Therapeutics Inc (TRDA)

TIPRANKS
·
Jun 03

Entrada Therapeutics posts corporate deck outlining Duchenne muscular dystrophy, DM1 clinical pipeline milestones

Reuters
·
Jun 02

Entrada Therapeutics clears 10 mg/kg Cohort 2 start in ELEVATE-45-201 DMD trial for ENTR-601-45

Reuters
·
Jun 02

Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 Mg/Kg in Entrada Therapeutics’ Elevate-45-201 Study

THOMSON REUTERS
·
Jun 02

Entrada Therapeutics - on Track to Report Elevate-45-201 Cohort 1 Data in Mid-2026

THOMSON REUTERS
·
Jun 02

Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics’ ELEVATE-45-201 Study

GlobeNewswire
·
Jun 02

Entrada Therapeutics grants 18,600 inducement RSUs to new hires under 2025 equity plan

Reuters
·
Jun 02

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Jun 02

Entrada director Bernhardt Zeiher acquires $29,316 Entrada common shares

Reuters
·
May 22

Entrada Therapeutics price target lowered to $10 from $19 at Roth Capital

TIPRANKS
·
May 09

HC Wainwright Downgrades Entrada Therapeutics to Neutral From Buy

MT Newswires Live
·
May 08

Entrada Therapeutics Cut to Neutral From Buy by HC Wainwright & Co.

Dow Jones
·
May 08

Entrada Therapeutics reports topline data from Cohort 1 of ELEVATE-44-201 study

TIPRANKS
·
May 08

BUZZ-Entrada sinks after Duchenne drug underwhelms in early trial

Reuters
·
May 08

Entrada Therapeutics Shares Decline on Duchenne Muscular Dystrophy Study Data

Dow Jones
·
May 08

BUZZ-U.S. STOCKS ON THE MOVE-Krispy Kreme, Tesla, Axon Enterprise

Reuters
·
May 08

Buy Rating Reaffirmed on TRDA as ENTR‑601‑44 Shows Clinically Meaningful Functional Gains and Higher-Dose Data Loom as Key Catalyst

TIPRANKS
·
May 08

Entrada Therapeutics Shares Slump 61% to $6.05 After Co's Duchenne Drug Misses Expectations in Trial

THOMSON REUTERS
·
May 07